Perioperative problems in Parkinson's disease and their management: Apomorphine with rectal domperidone

Canadian Journal of Neurological Sciences

Volumn 23, Issue 3, 1996, Pages 198-203

  Gálvez Jiménez, Néstor ^a   Lang, Anthony E ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CARBIDOPA; DOMPERIDONE; LEVODOPA;

ADULT; AGED; AKINESIA; CASE REPORT; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PATIENT CARE; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; RIGIDITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029784804     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100038518     Document Type: Review

References (62)

1. Tanner CM. Epidemiology of Parkinson's Disease. Neurol Clin 1992; 10(2): 317-329.
2. Rajput AH. Epidemiology of Parkinson's Disease. Can J Neurol Sci 1984; 11: 156-159.
3. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and morality. Ann Neurol 1984; 16: 278-282.
4. Marttila RJ. Epidemiology. In: Koller WC, ed. Handbook of Parkinson's Disease. New York: Marcel Dekker, Inc., 1987: 35-50.
5. Edmunds LH, Stephenson LW, Edie RN, Ratcliffe MB. Open-heart surgery in octogenarians. N Engl J Med 1988; 319: 131-136.
6. Easdown LJ, Tessler KJ, Minuk J. Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure. Can J Anaesth 1995; 42: 344-347.
7. Figa-Talamanca L, Gualandi C, DiMeo L, et al. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology 1985; 35: 258-261.
8. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994; 17: 243-259.
9. van Laar T, Jansen ENH, Neef C, Danhof M, Roos RAC. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's Disease: a study of five different suppositories. Mov Disord 1995; 10: 433-439.
10. van Laar T, Jansen ENH, Essink AWG, Neef C. Intranasal apomorphine in parkinsonian "on-off" fluctuations. Arch Neurol 1992; 49: 482-484.
11. Montastruc JL, Rascol O, Senard JM, et al. Sublingual apomorphine in Parkinson's Disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 1991; 14: 432-437.
12. Rascol O, Senard JM, Rascol A, Montastruc JL. Apomorphine test in parkinsonian syndromes. Lancet 1990; 336: 518
13. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990; 336: 32-34.
14. Bonuccelli U, Piccini P, Del Dotto P, et al. Apomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord 1993; 8: 158-164.
15. Hughes AJ, Lees AJ, Stern GM. Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin Neuropharmacol 1990; 13: 312-317.
16. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PAH. Subcutaneous apomorphine for on-off oscillations in Parkinson's Disease. Lancet 1988; 1260.
17. de Saint Victor J, Pollak P, Gervason C-L, Pettet J. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorhine. Mov Disord 1992; 7: 283-287.
18. Durif F, Deffond D, Dordain G, Toumilhac M. Apomorphine and diphasic dyskinesia. Clin Neuropharmacol 1994; 17: 99-102.
19. Stibe CMH, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 403-406.
20. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD. Goldstein M, Calne DB, ed. Recent Development in Parkinson's Disease. Vol. 2 Florham Park, New Jersey: Macmillan, 1987: 153-163.
21. Weiner WJ, Lang AE. Movement Disorders - A Comprehensive Survey. New York: Futura Publishing, 1989.
22. Chokroverty S. The spectrum of ventilatory disturbances in movement disorders. In: Chokroverty S., ed. Movement Disorders. U.S.A. PMA Publishing Corp., 1990: 365-392.
23. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459-1464.
24. Tisi GM. Preoperative evaluation of pulmonary function. Am Rev Respir Dis 1979; 119: 293-310.
25. Manning FC. Preoperative evaluation of the elderly patient. AFP 1989; 39: 123-128.
26. Ilson J, Braun N, Fahn S. Respiratory fluctuations in Parkinson's Disease. Neurology 1983; 33: 113.
27. Garlind T, Linderholm H. Hypoventilation syndrome in a case of chronic epidemic encephalitis. Acta Med Scand 1958; 333-349.
28. Granerus A, Jagenburg R, Nilsson NJ, Svanborg A. Respiratory disturbance during L-Dopa treatment of Parkinson's Syndrome. Acta Med Scand 1974; 195: 39-43.
29. Purdy A, Hahn A, Barnett HJM, et al. Familial fatal parkinsonism with aveolar hypoventilation and mental depression. Ann Neurol 1979; 6: 523-531.
30. Chokroverty S. Sleep apnoea and respiratory disturbances in multiple system atrophy with autonomic failure. In: Bannister R. ed. Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System. 2nd ed. Oxford: Oxford Medical Publications, 1988: 432-450.
31. Neu HC, Connolly JJ, Schwertley FW, Ladwig HA, Brody AW. Obstructive respiratory dysfunction in parkinsonian patients. Ann Rev Resp Dis 1967; 95: 33-47.
32. Paulson GD, Tafrate RH. Some "minor" aspects of parkinsonism, especially pulmonary function. Neurology 1970; 20: 14-17.
33. Nakano KK, Bass H, Tyler HR. Levodopa in Parkinson's Disease. Arch Intern Med 1972; 130: 346-348.
34. Zupnick HM, Brown LK, Miller A, Moros DA. Respiratory dysfunction due to L-dopa therapy for parkinsonism:diagnosis using serial pulmonary function tests and respiratory inductive plethysmography. Am J Med 1990; 89: 109-114.
35. Weiner WJ, Goetz CG, Nausieda PA, Klawans HL. Respiratory dyskinesias:extra pyramidal dysfunction and dyspnea. Ann Intern Med 1978; 88: 327-331.
36. Rosin AJ, Deveueux D, Eng N, Calne DB. Parkinsonism with "on-off" phenomena - intravenous treatment with levodopa after major abdominal surgery. Arch Neurol 1979; 36: 32-34.
37. Horowski R, Obeso JA. Lisuride: A direct dopamine agonist in the symptomatic treatment of Parkinson's Disease. In: Koller WC, Paulson G, ed. Therapy of Parkinson's Disease. 2nd ed. New York: Marcel Dekker, Inc, 1995: 219-248.
38. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993; 8: 263-270.
39. Strange PG. Multiple dopamine receptors: relevance for neurode-generative disorders. Biochem Soc Trans 1994; 22: 155-159.
40. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's Disease: clinical utility and lack of tolerance. Mov Disord 1995; 10: 37-43.
41. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232-238.
42. Edwards LL, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993; 33: 490-493.
43. Mathers SE, Kempster A, Law PJ, et al. Anal sphincter dysfunction in Parkinson's Disease. Arch Neurol 1989; 46: 1061-1064.
44. Edwards LL, Quigley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42: 726-732.
45. Rajput AH, Rozdilsky B. Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry 1976; 39: 1092-1100.
46. Sotolongo JR, Jr. Voiding dysfunction in Parkinson's Disease. Seminar Neurol 1988; 8: 166-169.
47. Corman LC. Neurologic conditions in the perioperative setting. In: Kammerer WS, Gross RJ, eds. Medical Consultation - The Internist on Surgical, Obstetric, and Psychiatric Services. Baltimore: Williams and Wilkins, 1990: 470-488.
48. Hayhurst MD. Preoperative pulmonary function testing. Respir Med 1993; 87: 161-163.
49. Broussolle E, Marion MH, Pollak P. Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet 1992; 340: 859-860.
50. Parkes JD. Domperidone and Parkinson's Disease. Clin Neuropharmacol 1986; 9: 517-532.
51. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone - A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24: 360-400.
52. Apps MCP, Sheaff PC, Ingram DA, Kennard C, Empey DW. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry 1985; 48: 1240-1245.
53. Anonymous. The causes of abnormal pulmonary function in Parkinson's Disease. Am Rev Respir Dis 1972; 105: 382-387.
54. Tzelepis GE, McCool FD, Friedman JH, Hoppin FG. Respiratory muscle dysfunction in Parkinson's Disease. Am Rev Respir Dis 1988; 138: 266-271.
55. Hardie RJ, Efthimiou J, Stern GM. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry 1986; 50: 1326.
56. Bogaard JM, Hovestadt A, Meerwald J, v.d.Meche FGA, Stigt J. Flow-volume curves in Parkinson's Disease. Bulletin Europeen de Physiopathologie Respiratoire 1987; 23: 4175.
57. Schiffman PL. A "saw-tooth" pattern in Parkinson's Disease. Chest 1985; 87: 124-126.
58. Vincken WG, Gauthier S, Dollfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders - a cause of airflow limitation. N Engl J Med 1984; 311: 438-442.
59. Corbin DOC, Williams AC. Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry 1987; 50: 821-822.
60. Vincken WG, Darauay CM, Cosio MG. Reversibility of upper airway obstruction after levodopa therapy in Parkinson's Disease. Chest 1989; 96: 210-212.
61. De Bruin PFC, De Bruin VMS, Lees AJ, Pride NB. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's Disease. Am Rev Respir Dis 1993; 148: 1576-1580.
62. D'Costa DF, Abbott RJ, Pye IF, Millac PAH. The apomorphine test in Parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991; 54: 870-872.